Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

医学 蛋白尿 临床终点 内科学 肾功能 肾病 安慰剂 肾脏疾病 临床试验 胃肠病学 肾 病理 内分泌学 糖尿病 替代医学
作者
Richard A. Lafayette,Jens Halkjaer Kristensen,Andrew M. Stone,Jürgen Floege,Vladimír Tesař,Hernán Trimarchi,Hong Zhang,Necmi Eren,Alexander Paliege,Heather N. Reich,Brad H. Rovin,Jonathan Barratt
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10405): 859-870 被引量:420
标识
DOI:10.1016/s0140-6736(23)01554-4
摘要

IgA nephropathy is a chronic immune-mediated kidney disease and a major cause of kidney failure worldwide. The gut mucosal immune system is implicated in its pathogenesis, and Nefecon is a novel, oral, targeted-release formulation of budesonide designed to act at the gut mucosal level. We present findings from the 2-year, phase 3 NefIgArd trial of Nefecon in patients with IgA nephropathy.In this phase 3, multicentre, randomised, double-blind, placebo-controlled trial, adult patients (aged ≥18 years) with primary IgA nephropathy, estimated glomerular filtration rate (eGFR) 35-90 mL/min per 1·73 m2, and persistent proteinuria (urine protein-creatinine ratio ≥0·8 g/g or proteinuria ≥1 g/24 h) despite optimised renin-angiotensin system blockade were enrolled at 132 hospital-based clinical sites in 20 countries worldwide. Patients were randomly assigned (1:1) to receive 16 mg/day oral capsules of Nefecon or matching placebo for 9 months, followed by a 15-month observational follow-up period off study drug. Randomisation via an interactive response technology system was stratified according to baseline proteinuria (<2 or ≥2 g/24 h), baseline eGFR (<60 or ≥60 mL/min per 1·73 m2), and region (Asia-Pacific, Europe, North America, or South America). Patients, investigators, and site staff were masked to treatment assignment throughout the 2-year trial. Optimised supportive care was also continued throughout the trial. The primary efficacy endpoint was time-weighted average of eGFR over 2 years. Efficacy and safety analyses were done in the full analysis set (ie, all randomly assigned patients). The trial was registered on ClinicalTrials.gov, NCT03643965, and is completed.Patients were recruited to the NefIgArd trial between Sept 5, 2018, and Jan 20, 2021, with 364 patients (182 per treatment group) randomly assigned in the full analysis set. 240 (66%) patients were men and 124 (34%) were women, and 275 (76%) identified as White. The time-weighted average of eGFR over 2 years showed a statistically significant treatment benefit with Nefecon versus placebo (difference 5·05 mL/min per 1·73 m2 [95% CI 3·24 to 7·38], p<0·0001), with a time-weighted average change of -2·47 mL/min per 1·73 m2 (95% CI -3·88 to -1·02) reported with Nefecon and -7·52 mL/min per 1·73 m2 (-8·83 to -6·18) reported with placebo. The most commonly reported treatment-emergent adverse events during treatment with Nefecon were peripheral oedema (31 [17%] patients, vs placebo, seven [4%] patients), hypertension (22 [12%] vs six [3%]), muscle spasms (22 [12%] vs seven [4%]), acne (20 [11%] vs two [1%]), and headache (19 [10%] vs 14 [8%]). No treatment-related deaths were reported.A 9-month treatment period with Nefecon provided a clinically relevant reduction in eGFR decline and a durable reduction in proteinuria versus placebo, providing support for a disease-modifying effect in patients with IgA nephropathy. Nefecon was also well tolerated, with a safety profile as expected for a locally acting oral budesonide product.Calliditas Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我是老大的应助被wjsbhsn采纳,获得10
刚刚
lydia发布了新的文献求助10
刚刚
1秒前
2秒前
勤奋的若冰完成签到 ,获得积分10
2秒前
张yusong发布了新的文献求助10
3秒前
4秒前
4秒前
与月舒完成签到,获得积分10
4秒前
草莓软糖完成签到,获得积分10
4秒前
戴好头盔搞科研完成签到,获得积分10
4秒前
4秒前
郑麻完成签到,获得积分10
5秒前
5秒前
忧郁的之槐完成签到 ,获得积分10
5秒前
molihuakai的应助被香蕉寒珊采纳,获得10
6秒前
春亦晚完成签到,获得积分10
6秒前
6秒前
6秒前
Deb发布了新的文献求助10
7秒前
CodeCraft的应助被草莓软糖采纳,获得10
7秒前
852的应助被神宝嘎li采纳,获得10
7秒前
蟹老板发布了新的文献求助10
8秒前
8秒前
wyt完成签到,获得积分10
8秒前
9秒前
陈鹿华完成签到 ,获得积分10
9秒前
wlin发布了新的文献求助10
9秒前
lili发布了新的文献求助10
9秒前
花样年华发布了新的文献求助150
9秒前
大模型的应助被Zheng采纳,获得10
9秒前
何曼慈发布了新的文献求助10
10秒前
隐形曼青的应助被Lily采纳,获得10
10秒前
cain完成签到 ,获得积分10
11秒前
11秒前
shi发布了新的文献求助10
11秒前
11秒前
Mimo发布了新的文献求助10
12秒前
苏小咩发布了新的文献求助10
13秒前
雪白冷荷完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572434
关于积分的说明 21825655
捐赠科研通 7779988
什么是DOI,文献DOI怎么找? 3433852
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480148